Prescription

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Retrieved on: 
Wednesday, February 14, 2024

"We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.

Key Points: 
  • "We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

Retrieved on: 
Wednesday, February 14, 2024

Gibbs Law Group announces that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.

Key Points: 
  • Gibbs Law Group announces that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.
  • Our investigation concerns whether Amylyx Pharmaceuticals has violated federal securities laws by providing false or misleading statements to investors.
  • On November 9, 2023, biotechnology company Amylyx Pharmaceuticals announced its 2023 Q3 financial results and hosted a conference call to discuss these results.
  • Following this news, Amylyx Pharmaceuticals shares plummeted over 31% on November 9, 2023, causing significant harm to investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 14, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

AMYLYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Retrieved on: 
Monday, February 12, 2024

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Amylyx Pharmaceuticals, Inc. (“Amylyx or the “Company”) (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Amylyx Pharmaceuticals, Inc. (“Amylyx or the “Company”) (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Monday, February 12, 2024

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Monday, February 12, 2024

), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx’s top current and former executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx’s top current and former executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Amylyx class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Amylyx class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Amylyx class action lawsuit.

Online Pharmacies Maintain Popularity But Now Face Usability and Cost Challenges

Retrieved on: 
Monday, February 12, 2024

With an overwhelming majority of patients turning to digital platforms for their healthcare needs, the adoption of online pharmacies has surged.

Key Points: 
  • With an overwhelming majority of patients turning to digital platforms for their healthcare needs, the adoption of online pharmacies has surged.
  • However, new research by Software Advice reveals patients now report usability challenges with the apps.
  • This change suggests that economic factors, including inflation, are influencing the benefits once offered by online pharmacies.
  • For insights and recommendations on selecting EHR or practice management platforms with online pharmacy integration, read the full report on Software Advice .

AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Saturday, February 10, 2024

), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx's top current and former executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx's top current and former executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Amylyx class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Amylyx class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Amylyx class action lawsuit.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 10, 2024

Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis ("ALS"), also known as Lou Gehrig's disease, and other neurodegenerative diseases.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.